Carbamic acid, (2-aminoethyl)butyl-, 1,1-dimethylethyl ester | 105628-65-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Carbamic acid, (2-aminoethyl)butyl-, 1,1-dimethylethyl ester
• 英文别名: tert-butyl N-(2-aminoethyl)-N-butylcarbamate
• CAS: 105628-65-7
• 化学式: C₁₁H₂₄N₂O₂
• 分子量: 216.32
• InChiKey: DXZTVEUCBIJSGX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME<br/>[FR] COMPOSÉS DÉRIVÉS DE 1,3,4-OXADIAZOLE SULFONAMIDE SERVANT D'INHIBITEUR DE L'HISTONE DÉSACÉTYLASE 6, ET COMPOSITION PHARMACEUTIQUE COMPRENANT CEUX-CI
  申请人：CHONG KUN DANG PHARMACEUTICAL CORP

  公开号：WO2017018803A1

  公开（公告）日：2017-02-02

  The present invention relates to novel compounds represented by the formula I having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. (I) The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present invention have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases.

  本发明涉及具有组蛋白去乙酰化酶6（HDAC6）抑制活性的新化合物，其立体异构体或药学上可接受的盐，其用于制备治疗药物，含有相同化合物的药物组合物，使用该组合物治疗疾病的方法，以及制备新化合物的方法。根据本发明，这些新化合物、其立体异构体或药学上可接受的盐具有组蛋白去乙酰化酶（HDAC）抑制活性，并且对于预防或治疗HDAC6介导的疾病有效。
• ErbB/BTK inhibitors
  申请人：Dizal (Jiangsu) Pharmaceutical Co., Ltd.

  公开号：US11007198B2

  公开（公告）日：2021-05-18

  Disclosed are compounds inhibiting ErbBs (e.g., EGFR or Her 2), especially mutant forms of ErbBs, and BTK, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat ErbBs (especially mutant forms of ErbBs) or BTK associated diseases, including cancer.

  所公开的是抑制ErbBs（如表皮生长因子受体或Her 2），特别是ErbBs的突变形式，以及BTK的化合物、其药学上可接受的盐、水合物、溶液或立体异构体，以及包含这些化合物的药物组合物。化合物和药物组合物可有效治疗 ErbBs（尤其是 ErbBs 的突变形式）或 BTK 相关疾病，包括癌症。
• CAMKII INHIBITORS AND USES THEREOF
  申请人：The Johns Hopkins University

  公开号：EP3189052B1

  公开（公告）日：2021-11-03
• ERBB/BTK INHIBITORS
  申请人：Dizal (Jiangsu) Pharmaceutical Co., Ltd.

  公开号：US20200316079A1

  公开（公告）日：2020-10-08

  Disclosed are compounds inhibiting ErbBs (e.g., EGFR or Her 2), especially mutant forms of ErbBs, and BTK, pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat ErbBs (especially mutant forms of ErbBs) or BTK associated diseases, including cancer.